Michael A. Metzger - 25 Oct 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President and COO, Director
Signature
/s/ Michael A. Metzger
Issuer symbol
SNDX
Transactions as of
25 Oct 2021
Net transactions value
-$728,960
Form type
4
Filing time
27 Oct 2021, 16:11:34 UTC
Previous filing
28 Sep 2021
Next filing
15 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $321,869 +44,704 +253% $7.20 62,363 25 Oct 2021 Direct
transaction SNDX Common Stock Sale $855,335 -44,704 -72% $19.13 17,659 25 Oct 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $117,331 +16,296 +92% $7.20 33,955 26 Oct 2021 Direct
transaction SNDX Common Stock Sale $312,825 -16,296 -48% $19.20 17,659 26 Oct 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -44,704 -100% $0.000000* 0 25 Oct 2021 Common Stock 44,704 $7.20 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -16,296 -100% $0.000000* 0 26 Oct 2021 Common Stock 16,296 $7.20 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The share price ranged from $19.00 to $19.48
F3 The sales price ranged from $19.01 to $19.33
F4 This option is fully vested.